U.S. Over the Counter Drugs Market Size, Share & COVID-19 Impact Analysis, By Product Type (Analgesics, Cold & Cough Remedies, Digestives & Intestinal Remedies, Skin Treatment, Vitamins & Minerals, and Others), By Distribution Channel (Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

Last Updated: February 10, 2025 | Format: PDF | Report ID: FBI107911

THANK YOU

FOR YOUR INTEREST IN OUR REPORT

Are you interested in exploring our consulting services?

I want to learn more about:

Competitive Intelligence Opportunity Assessment Distribution & Supply Chain Analysis Book a consultation to discuss your needs

Market Entry Strategy Go-to-market Strategy Others (Please specify)

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
Key Insights
1. New Product Launches, By Key Players
2. Recent Industry Developments – Partnerships, Mergers & Acquisitions
3. Impact of Covid-19 on the Market
U.S. Over The Counter Drugs Analysis, Insights and Forecast, 2019-2030
1. Market Analysis, Insights and Forecast – By Product Type
  1. Analgesics
  2. Cold & Cough Remedies
  3. Digestives & Intestinal Remedies
  4. Skin Treatment
  5. Vitamins & Minerals
  6. Others
2. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Drug Stores & Retail Pharmacies
  2. Hospital Pharmacies
  3. Online Pharmacies
Competitive Analysis
1. U.S. Market Share Analysis (2022)
2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  1. Johnson & Johnson Services Inc.
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  2. Bayer AG
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  3. Novartis AG
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  4. Sanofi S.A
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  5. Pfizer
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  6. GlaxoSmithKline Plc
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  7. Boehringer Ingelheim International GmbH
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  8. Reckitt Benckiser Group PLC
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  9. Takeda Pharmaceutical Company Ltd.
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)
  10. Perrigo Company plc
    1. Overview,
    2. Product,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. financials (Based on Availability)